See more : Laser Photonics Corporation (LASE) Income Statement Analysis – Financial Results
Complete financial analysis of Vivesto AB (OASM.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vivesto AB, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- BSR Real Estate Investment Trust (HOM-U.TO) Income Statement Analysis – Financial Results
- AeroEdge Co., Ltd. (7409.T) Income Statement Analysis – Financial Results
- East Africa Metals Inc. (EAM.V) Income Statement Analysis – Financial Results
- Taiga Motors Corporation (TAIMF) Income Statement Analysis – Financial Results
- Orezone Gold Corporation (ORE.TO) Income Statement Analysis – Financial Results
Vivesto AB (OASM.ST)
About Vivesto AB
Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. The company offers Apealea (paclitaxel micellar) for the treatment of ovarian cancer. Its products portfolio includes Docetaxel micellar, a patented formulation that combines XR-17 with docetaxel, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil, which has completed Phase I clinical trial for the treatment of ovarian cancer. The company's animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Oasmia Pharmaceutical AB (publ) was incorporated in 1988 and is headquartered in Solna, Sweden.
Source: https://incomestatements.info
Category: Stock Reports